TW200303213A - Lyophilized monoclonal antibody compositions - Google Patents

Lyophilized monoclonal antibody compositions Download PDF

Info

Publication number
TW200303213A
TW200303213A TW091133319A TW91133319A TW200303213A TW 200303213 A TW200303213 A TW 200303213A TW 091133319 A TW091133319 A TW 091133319A TW 91133319 A TW91133319 A TW 91133319A TW 200303213 A TW200303213 A TW 200303213A
Authority
TW
Taiwan
Prior art keywords
composition
item
antibody
patent application
scope
Prior art date
Application number
TW091133319A
Other languages
English (en)
Chinese (zh)
Inventor
Tracy Chen
Glen Tolman
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of TW200303213A publication Critical patent/TW200303213A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW091133319A 2001-11-09 2002-11-08 Lyophilized monoclonal antibody compositions TW200303213A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34206301P 2001-11-09 2001-11-09

Publications (1)

Publication Number Publication Date
TW200303213A true TW200303213A (en) 2003-09-01

Family

ID=23340162

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091133319A TW200303213A (en) 2001-11-09 2002-11-08 Lyophilized monoclonal antibody compositions

Country Status (7)

Country Link
EP (1) EP1455822A4 (fr)
JP (1) JP2005508992A (fr)
AR (1) AR037304A1 (fr)
CA (1) CA2466641A1 (fr)
MX (1) MXPA04004459A (fr)
TW (1) TW200303213A (fr)
WO (1) WO2003041637A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982080B2 (en) 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
US20110236391A1 (en) * 2008-12-09 2011-09-29 Hanns-Christian Mahler Method for obtaining an excipient-free antibody solution
WO2012028683A1 (fr) 2010-09-02 2012-03-08 Novartis Ag Système de gel d'anticorps pour administration de médicament prolongée
TWI616204B (zh) 2010-11-05 2018-03-01 諾華公司 Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途
KR20250093620A (ko) * 2017-09-15 2025-06-24 암젠 인크 치료 단백질의 동결건조된 약학적 제형을 위한 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE68524T1 (de) * 1985-07-09 1991-11-15 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
WO1993000807A1 (fr) * 1991-07-03 1993-01-21 Cryolife, Inc. Procede de stabilisation de biomateriaux
WO1993014191A1 (fr) * 1992-01-21 1993-07-22 Cryopharm Corporation Procede de congelation de cellules et de matieres analogues a des cellules
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
JP4502406B2 (ja) * 1995-06-07 2010-07-14 クアドラント、ドラッグ、デリバリー、リミテッド 乾燥発泡ガラスマトリックス内に物質を安定に配合する方法及びそれによって得られた組成物
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
KR20100031769A (ko) * 2000-12-28 2010-03-24 알투스 파마슈티컬스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법

Also Published As

Publication number Publication date
MXPA04004459A (es) 2005-05-16
EP1455822A2 (fr) 2004-09-15
WO2003041637A2 (fr) 2003-05-22
AR037304A1 (es) 2004-11-03
CA2466641A1 (fr) 2003-05-22
EP1455822A4 (fr) 2004-12-29
JP2005508992A (ja) 2005-04-07
WO2003041637A3 (fr) 2004-01-22

Similar Documents

Publication Publication Date Title
CA2272245C (fr) Preparations pharmaceutiques lyophilisees stables d'anticorps monoclonaux ou polyclonaux
US10786567B2 (en) Stable anti-PD-1 antibody pharmaceutical preparation and application thereof in medicine
AU2013255413C1 (en) Pharmaceutical formulations of TNF-alpha antibodies
ES2897500T3 (es) Formulaciones de anticuerpos T1h
CA2037884C (fr) Preparations stabilisees renfermant de la gonadotrophine
CN1886158B (zh) 包含抗egf受体抗体的药物制剂
BRPI0710508A2 (pt) composição de pepticorpo terapêutico liofilizado, métodos para fabricar um papticorpo terapêutico liofilizado e para preparar uma composição de pepticorpo terapêutico liofilizado e para preparar uma composição farmacêutica aquosa
JP6761015B2 (ja) 弱毒生アルファウイルス製剤のための組成物および方法
EP2258402A2 (fr) Composition sèche
TWI243057B (en) Formulations for protection of peg-interferon alpha conjugates
MXPA04004459A (es) Composiciones liofilizadas de anticuerpo monoclonal.
AU2002337895A1 (en) Lyophilized monoclonal antibody compositions
JP7630625B2 (ja) 改善された凍結乾燥製剤
WO2016059593A1 (fr) Composition injectable stable de médicaments protéiques et procédé de préparation associé
EP2727584A1 (fr) Gaz de ventilation destinés à être utilisés dans le séchage, le stockage et/ou la reconstitution des biomolécules